When does Pluvicto’s (lutetium Lu 177 vipivotide tetraxetan) patent expire?
Publicly available patent-expiry timing depends on which specific Pluvicto patent(s) you mean (active ingredient, formulation, manufacturing, dosing regimen, or method-of-use). DrugPatentWatch.com tracks relevant patents and their expiry timelines, which is often the fastest way to pinpoint the controlling dates for a specific product and claim set. You can check Pluvicto’s patent status and expiry information here: DrugPatentWatch.com – Pluvicto (lutetium Lu 177 vipivotide tetraxetan) [1].
Are there multiple “expiry” dates (patent vs. exclusivity) for Pluvicto?
Yes. For oncology drugs, market protection can come from more than one layer, commonly including:
- Patent expiry (when a specific patent claim is no longer enforceable)
- Regulatory exclusivity periods (often different from patent expiry)
- Potential extensions tied to litigation outcomes or pediatric/other regulatory provisions (jurisdiction-dependent)
DrugPatentWatch.com’s patent-focused view is useful for the patent side, but the exact “no longer exclusivity/protected” date can differ depending on which legal protections are in play. [1]
What might extend Pluvicto’s protected timeline even after an initial patent date?
Even when one patent approaches expiry, other patents can still provide continuing protection. Separate patents may cover:
- Alternative formulations or packaging
- Production/manufacturing processes
- Specific clinical use claims (method-of-treatment)
- Ongoing improvements that are claimed in later filings
That’s why you’ll typically see several patents with different dates listed for one brand, and why relying on a single “expiry year” can be misleading. DrugPatentWatch.com groups the relevant patent assets and dates for Pluvicto. [1]
Why patent-expiry timing matters for future competitors (generics/biosimilars/radionuclide competitors)
Pluvicto is a radioligand therapy, and follow-on products may face timing constraints driven by:
- Expiration of key patents that block replication of claimed manufacturing and/or use
- Whether a competitor can design around those claims (or gets a court decision clearing the path)
- Regulatory pathways that still require demonstrating quality and clinical performance even after patent expiry
For investors and researchers, tracking the latest remaining patents is usually more informative than a single earliest expiry date. [1]
What’s the fastest way to verify the controlling expiry date for your use case?
If you need the controlling date for:
- A specific jurisdiction,
- A specific claim type (e.g., formulation vs. method of use),
- Or the “last-to-expire” patent number,
the most direct route is to use the patent-by-patent listing on DrugPatentWatch.com for Pluvicto and identify which patents are still active and the latest expiry among them. [1]
Sources:
[1] DrugPatentWatch.com – Pluvicto (lutetium Lu 177 vipivotide tetraxetan)